Tocqueville Asset Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Tocqueville Asset Management’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,125	Closed	-$17K	–	636
2022 Q3	$17K	Sell	2,125 -550	-21%	-$9.1K	﹤0.01%	593
2022 Q2	$56K	Hold	2,675	–	–	﹤0.01%	654
2022 Q1	$101K	Hold	2,675	–	–	﹤0.01%	692
2021 Q4	$150K	Sell	2,675 -1,025	-28%	-$68.8K	﹤0.01%	720
2021 Q3	$267K	Buy	3,700 +2,260	+157%	+$173K	﹤0.01%	651
2021 Q2	$138K	Sell	1,440 -888	-38%	-$98.1K	﹤0.01%	721
2021 Q1	$344K	Sell	2,328 -275	-11%	-$49.8K	0.01%	615
2020 Q4	$364K	Buy	2,603 +1,585	+156%	+$257K	0.01%	591
2020 Q3	$154K	Buy	+1,018	New	+$166K	﹤0.01%	634

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Tocqueville Asset Management's NBSE Position: Q4 2022 in Review

Tocqueville Asset Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2022, closing a stake of 2,125 shares — an estimated $17K sold.

Tocqueville Asset Management first reported a position in NBSE in Q3 2020 and held it in 9 quarters. The position peaked at $364K in Q4 2020. 34 funds tracked by Wall St. Rank hold NBSE as of Q4 2022.

Tocqueville Asset Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Tocqueville Asset Management sold 2,125 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $17K.
Tocqueville Asset Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
Tocqueville Asset Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $364K in Q4 2020.
34 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Tocqueville Asset Management's 13F filing for Q4 2022, filed 9 Feb 2023.